BCRX
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- BioCryst received Japanese approval for ORLADEYO in pediatric patients with hereditary angioedemaAug 25, 2026
- BioCryst signed a European licensing agreement for Navenibart in hereditary angioedemaMay 4, 2026
- BioCryst completed acquisition of Astria Therapeutics, expanding HAE leadershipJan 23, 2026
- BioCryst announces FDA approval of ORLADEYO® oral pellets for HAE patients aged 2 to under 12 yearsDec 12, 2025
- BioCryst presents new data highlighting burden of HAE on pediatric patients and caregivers and sustained reduction of attacks with one year of ORLADEYO® treatmentNov 6, 2025